SCHEMBL2431235

SCHEMBL2431235

O=Cc1ccc(-c2cn3cc(F)ccc3n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.61
ALDH1A3 P47895 7/20 0.56
CYP11B1 P15538 3/20 0.52
CYP11B2 P19099 3/20 0.52
CLK1 P49759 1/20 0.52
DYRK1A Q13627 1/20 0.52
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
PAX8 Q06710 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 1/20 0.49
MITF O75030 1/20 0.49
KDM5A P29375 1/20 0.49
KDM5C P41229 1/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A2 O94788 1/20 0.47
POLB P06746 2/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22906630 0.85 APP (0.73) APPALDH1A3CYP11B1CYP11B2CLK1
SCHEMBL9488366 0.83 NPC1 (0.73) APPALDH1A3NPC1RAB9AALDH1A1
SCHEMBL18003621 0.83 ALDH1A3 (0.51) APPALDH1A3CYP11B1CYP11B2CLK1
SCHEMBL3885303 0.82 APP (0.58) APPALDH1A3CYP11B1CYP11B2CLK1
SCHEMBL2429037 0.82 APP (0.61) APPALDH1A3NPC1RAB9AALDH1A1
SCHEMBL2426291 0.82 APP (0.61) APPALDH1A3CLK1DYRK1ANPC1
SCHEMBL21708014 0.81 ALDH1A3 (0.82) APPALDH1A3CYP11B1CYP11B2CLK1
SCHEMBL19763360 0.80 NPC1 (0.68) APPALDH1A3NPC1RAB9AALDH1A1
SCHEMBL1691421 0.80 NPC1 (0.75) APPALDH1A3CYP11B1CYP11B2CLK1
SCHEMBL2258357 0.80 NPC1 (0.66) APPALDH1A3CYP11B1CYP11B2CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 APP 1/4885ALDH1A3 3748/4885CYP11B1 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.